Pancreatic Cancer Research

Clinical trialPhase 1Recruiting

PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI

PET Imaging of Tumors in Pancreas, Bile Ducts, Stomach and Ovaries by a Novel Tracer, 68Ga-FAPI-46 = Fibroblast Activation Protein Inhibitor

NCT05172310↗ ClinicalTrials.gov, retrieved 4 November 2026

Outcome
Ongoing
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Start
2 June 2021
Expected end
31 March 2029
Enrollment
410 participants
Sites
1
Primary outcomes
Diagnostic accuracy of FAPI-PET/CT in primary tumors
Sponsor
Other
Results posted
No
Last update
29 December 2021

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.

Try

Papers 10